Alissandra Hillis
alissandra-hillis.bsky.social
Alissandra Hillis
@alissandra-hillis.bsky.social
Postdoctoral researcher at MIT @mvhlab.bsky.social
Alum of MIT 5-7 and
Harvard BBS @alextoker.bsky.social
she/her
Reposted by Alissandra Hillis
AND IT'S DONE! A 🧵 on our recent article now out in @natsmb.nature.com! Co-led with @abbybartlett.bsky.social, Pagliarini Lab, @judisimcox.bsky.social, we find ACAD10/11 are NOT like other acyl-CoA dehydrogenases and instead catabolize atypical lipids called 4-hydroxy acids 🤯 doi.org/10.1038/s415...
ACAD10 and ACAD11 enable mammalian 4-hydroxy acid lipid catabolism - Nature Structural & Molecular Biology
Rashan, Bartlett and colleagues show that mammalian 4-hydroxy fatty acids are primarily catabolized by ACAD10 and ACAD11 (atypical mitochondrial and peroxisomal acyl-CoA dehydrogenases, respectively) ...
doi.org
June 22, 2025 at 11:30 PM
Reposted by Alissandra Hillis
Happy Pi Day! MVH Lab's two delicious contributions to Pi day:
March 14, 2025 at 9:05 PM
Reposted by Alissandra Hillis
Looking at human kidney cancer, we profiled nutrient levels in the tumor environment and found they are similar to nutrient levels in healthy kidney tissue, suggesting tumors must work within constraints of nutrients available rather than change nutrient environment. elifesciences.org/articles/95652
Metabolite profiling of human renal cell carcinoma reveals tissue-origin dominance in nutrient availability
Assessing metabolites in renal cell carcinoma and kidney tissue suggests cancers adapt rather than dictate nutrient availability.
elifesciences.org
November 23, 2024 at 11:16 PM
Reposted by Alissandra Hillis
Published a few weeks ago in Cancer Research, we show benefit of targeting HMCR with pitavastatin in combo with AKT inhibitors in TNBC. Many amazing people contributed, led by the magnificently talented @alissandra-hillis.bsky.social! Looking to initiate new clinical trials based on this combo. 🧪
Targeting Cholesterol Biosynthesis with Statins Synergizes with AKT Inhibitors in Triple-Negative Breast Cancer
Two FDA-approved compounds, AKT inhibitors and pitavastatin, synergize to induce cell death in triple-negative breast cancer, motivating evaluation of the efficacy of this combination in clinical tria...
aacrjournals.org
November 20, 2024 at 12:09 PM
Reposted by Alissandra Hillis
Great to be posting science again!!
Very proud of this work, thanks to a wonderful collaboration with Forest White lab at MIT, Cantley lab at DFCI, and leb by the amazingly talented @alissandra-hillis.bsky.social! Published as fully @openaccess.bsky.social in PNAS.
www.pnas.org/doi/10.1073/...
November 17, 2024 at 7:25 AM